SD 101 - Dynavax Technologies

Drug Profile

SD 101 - Dynavax Technologies

Alternative Names: SD101 - Dynavax

Latest Information Update: 06 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dynavax Technologies
  • Developer Dynavax Technologies; Merck & Co; National Cancer Institute (USA); Stanford University School of Medicine; University of California, Davis
  • Class Antineoplastics; Oligodeoxyribonucleotides
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II B cell lymphoma; Follicular lymphoma; Head and neck cancer; Lymphoma; Malignant melanoma
  • Phase I Haematological malignancies
  • No development reported Hepatitis C

Most Recent Events

  • 04 Jun 2018 Updated efficacy and adverse events data from the phase I/II SYNERGY-001/KEYNOTE-184 trial in Malignant melanoma presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 17 May 2018 Additional efficacy and adverse events data from a phase Ib/II trial in Malignant melanoma and Head and neck cancer released by Dynavax Technologies
  • 16 Apr 2018 Interim efficacy and adverse events data from a phase Ib/II trial in Melanoma and Head and neck cancer released by Dynavax Technologies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top